Memantine Treatment of Compulsive Buying

Study Overview
=================
Brief Summary
-----------------
This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Detailed Description
-----------------
The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Official Title
-----------------
Memantine Treatment of Compulsive Buying: An Open-Label Study

Conditions
-----------------
Compulsive Buying

Intervention / Treatment
-----------------
* Drug: Memantine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women age 18-65 current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB) buying behavior within 2 weeks prior to enrollment Exclusion Criteria: infrequent buying (i.e. less than one time per week) that does not meet proposed criteria for CB unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen history of seizures myocardial infarction within 6 months current pregnancy or lactation, or inadequate contraception in women of childbearing potential a need for medication other than memantine with possible psychotropic effects or unfavorable interactions; clinically significant suicidality; current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID current or recent (past 3 months) DSM-IV substance abuse or dependence; positive urine drug screen at screening initiation of psychotherapy or behavior therapy within 3 months prior to study baseline previous treatment with memantine treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Memantine<br>10-30mg, memantine | Drug: Memantine<br>* 10-30mg, by mouth, daily<br>* Other names: Namenda;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS) | The CB-YBOCS is a reliable and valid, 10-item, clinician-administered scale that rates buying symptoms within the last seven days, on a severity scale from 0 to 4 for each item (total scores range from 0 to 40 with higher scores reflecting greater illness severity). Scores ranging from 0 to 10 reflect minimal or mild symptoms; scores from 11 to 20 suggest moderate symptoms; severe symptoms are associated with scores from 21 to 30; and scores greater than 30 reflect extreme buying symptoms | from study start to study end (8-weeks) and is Investigator rated | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Buying, Shopping, Impulse Control